Studi scientifici principali
- Indicazioni terapeutiche approvate da EMA
- Hézode C. et al., Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial, Lancet. 2015 Mar;
- Sulkowski MS. Et al., Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.JAMA. 2015 Mar;
- Chayama K. et al., Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015 May;
- Poordad F. et al., ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May
- Ferenci P., ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May
- Zeuzem S. et al, Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Ap
- Feld JJ et al., Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr
- Kwo PY et al., An interferon-free antiviral regimen for HCV after liver transplantation N Engl J Med. 2014 Dec
- a - TURQUOISE-III Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for genotype 1b with cirrhosis - Feld JJ. J Hepatol 2016; 64:301-7
- X – Co-Formulated Ombitasvir and Paritaprevir/ritonavir with ribavirinm in adults with Hepatitis C Virus Genotype 4 infection and Cirrhosis /AGATE-I): a randomised open-label trial
- Asselah et al. – Lancet Gastroenterology 2016
